nach oben

Erschienen in:

26.05.2020 | Review

Fertility and infertility implications in rheumatoid arthritis; state of the art

verfasst von: Abolfazl Fattah, Amirhooman Asadi, Mohammad Reza Hooshangi Shayesteh, Forough Hatefi Hesari, Sirous Jamalzehi, Mojtaba Abbasi, Mohammad Javad Mousavi, Saeed Aslani

Erschienen in: Inflammation Research | Ausgabe 8/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

A bulk of investigations imply that women with rheumatoid arthritis (RA) deliver fewer children in comparison to healthy women.

Purpose

This review article attempts to clarify the involvement of infertility-related issues in both RA men and women. Moreover, the effect of RA disease on the fertility quality and quantity will be discussed.

Results

Declined fertility rate in RA women seems to stem from modified inflammatory settings, advanced maternal age, limited sexual activity, and adverse effects of drugs on ovarian function. Women with RA may have smaller families and seem to be slower to conceive relative to their peer women. The chance of gestation in RA women may drop due to suppressed sexual function through pain and fatigue. In addition, treatment of RA women with non-steroidal anti-inflammatory drugs (NSAIDs) may prevent ovulation and therefore hinder the conception.

Conclusions

A complex interaction between RA disease and fertility related issues is present. Despite an increase rate of infertility in RA females or males, the mechanisms involved in this outcome is still unknown. Plausible causes of the decreased fertility rate in RA patients might be due to inflammatory cytokines, suppressed sexual activity, drug treatments, mother age, personal choice, or a combination of these elements.

Wallenius M, Skomsvoll JF, Irgens LM, Salvesen KÅ, Nordvåg B-Y, Koldingsnes W, et al. Fertility in women with chronic inflammatory arthritides. Rheumatology. 2011;50:1162–7.PubMed

Wallenius M, Skomsvoll J, Irgens L, Salvesen K, Nordvåg B, Koldingsnes W, et al. Parity in patients with chronic inflammatory arthritides childless at time of diagnosis. Scand J Rheumatol. 2012;41:202–7.PubMed

Skomsvoll JF, Ostensen M, Baste V, Irgens LM. Number of births, interpregnancy interval, and subsequent pregnancy rate after a diagnosis of inflammatory rheumatic disease in Norwegian women. J Rheumatol. 2001;28:2310–4.PubMed

Förger F, Vallbracht I, Helmke K, Villiger PM, Ostensen M. Pregnancy mediated improvement of rheumatoid arthritis. Swiss Med Wkly. 2012;142:w13644.PubMed

Østensen M, Villiger PM, Förger F. Interaction of pregnancy and autoimmune rheumatic disease. Autoimmun Rev. 2012;11:A437–A446446.PubMed

Østensen M, Villiger PM. The remission of rheumatoid arthritis during pregnancy. Semin Immunopathol. 2007;29:185–91. https://doi.org/10.1007/s00281-007-0072-5.CrossRefPubMed

Förger F, Villiger PM. Immunological adaptations in pregnancy that modulate rheumatoid arthritis disease activity. Nat Rev Rheumatol. 2020;16:113–22. https://doi.org/10.1038/s41584-019-0351-2.CrossRefPubMed

Del Junco D, Annegers J, Coulam C, Luthra HS. The relationship between rheumatoid arthritis and reproductive function. Br J Rheumatol. 1989;28:33.PubMed

Tsepelidis S, Devreker F, Demeestere I, Flahaut A, Gervy C, Englert Y. Stable serum levels of anti-Müllerian hormone during the menstrual cycle: a prospective study in normo-ovulatory women. Hum Reprod. 2007;22:1837–40.PubMed

10.

Leverenz DL, Eudy AM, Jayasundara M, Haroun T, McDaniel G, Nowell WB, et al. Contraception methods used by women with rheumatoid arthritis and psoriatic arthritis. Clin Rheumatol. 2019;38:1207–12.PubMed

11.

Provost M, Eaton JL, Clowse ME. Fertility and infertility in rheumatoid arthritis. Curr Opin Rheumatol. 2014;26:308–14.PubMed

12.

Katz PP. Childbearing decisions and family size among women with rheumatoid arthritis. Arthritis Care Res. 2006;55:217–23.

13.

Clowse ME, Chakravarty E, Costenbader KH, Chambers C, Michaud K. Effects of infertility, pregnancy loss, and patient concerns on family size of women with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res. 2012;64:668–74.

14.

Eudy AM, McDaniel G, Hurd WW, Clowse ME. Fertility and ovarian reserve among women with rheumatoid arthritis. J Rheumatol. 2019;46:455–9.PubMed

15.

Brouwer J, Laven JS, Hazes JM, Schipper I, Dolhain RJ. Levels of Serum anti-müllerian hormone, a marker for ovarian reserve, in women with rheumatoid arthritis. Arthritis Care Res. 2013;65:1534–8.

16.

Silman A, Roman E, Beral V, Brown A. Adverse reproductive outcomes in women who subsequently develop rheumatoid arthritis. Ann Rheum Dis. 1988;47:979.PubMedPubMedCentral

17.

Spector TD, Silman A. Is poor pregnancy outcome a risk factor in rheumatoid arthritis? Ann Rheum Dis. 1990;49:12.PubMedPubMedCentral

18.

Nørgård BM, Larsen MD, Friedman S, Knudsen T, Fedder J. Decreased chance of a live born child in women with rheumatoid arthritis after assisted reproduction treatment: a nationwide cohort study. Ann Rheum Dis. 2019;78:328–34.PubMed

19.

Chakravarty EF, Nelson L, Krishnan E. Obstetric hospitalizations in the United States for women with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheumatol. 2006;54:899–907.

20.

Lin H, Chen S, Lin H, et al. Increased risk of adverse pregnancy outcomes in women with rheumatoid arthritis: a nationwide population-based study. Ann Rheum Dis. 2010;69:715–7.PubMed

21.

Bowden AP, Barrett JH, Fallow W, Silman AJ. Women with inflammatory polyarthritis have babies of lower birth weight. J Rheumatol. 2001;28:355–9.PubMed

22.

Kishore S, Mittal V, Majithia V. Obstetric outcomes in women with rheumatoid arthritis: results from nationwide inpatient sample database 2003–2011✰. Semin Arthritis Rheum. 2019;49(2):236–40.PubMed

23.

Aljary H, Czuzoj-Shulman N, Spence AR, Abenhaim HA. Pregnancy outcomes in women with rheumatoid arthritis: a retrospective population-based cohort study. J Maternal-Fetal Neonatal Med. 2020;33(4):618–24. https://doi.org/10.1080/14767058.2018.1498835.CrossRef

24.

Jethwa H, Lam S, Smith C, Giles I. Does rheumatoid arthritis really improve during pregnancy? A systematic review and metaanalysis. J Rheumatol. 2019;46:245–50.PubMed

25.

Jabbour H, Sales K. Prostaglandin receptor signalling and function in human endometrial pathology. Trends Endocrinol Metab. 2004;15:398–404.PubMed

26.

Rashid NA, Lalitkumar S, Lalitkumar PG, Gemzell-Danielsson K. Endometrial receptivity and human embryo implantation. Am J Reprod Immunol. 2011;66:23–30.PubMed

27.

Gemzell-Danielsson K, Hamberg M. Endocrinology: the effect of antiprogestin (RU 486) and prostaglandin biosynthesis inhibitor (naproxen) on uterine fluid prostaglandin F2α concentrations. Hum Reprod. 1994;9:1626–30.PubMed

28.

King AE, Critchley HO. Oestrogen and progesterone regulation of inflammatory processes in the human endometrium. J Steroid Biochem Mol Biol. 2010;120:116–26.PubMed

29.

Dawood MY. Nonsteroidal anti-inflammatory drugs and reproduction. Am J Obstet Gynecol. 1993;169:1255–65.PubMed

30.

Eppig JJ. Prostaglandin E2 stimulates cumulus expansion and hyaluronic acid synthesis by cumuli oophori isolated from mice. Biol Reprod. 1981;25:191–5.PubMed

31.

Hizaki H, Segi E, Sugimoto Y, Hirose M, Saji T, Ushikubi F, et al. Abortive expansion of the cumulus and impaired fertility in mice lacking the prostaglandin E receptor subtype EP2. Proc Natl Acad Sci. 1999;96:10501–6.PubMedPubMedCentral

32.

Reich R, Daphna-Iken D, Chun S, Popliker M, Slager R, Adelmann-Grill B, et al. Preovulatory changes in ovarian expression of collagenases and tissue metalloproteinase inhibitor messenger ribonucleic acid: role of eicosanoids. Endocrinology. 1991;129:1869–75.PubMed

33.

Markosyan N, Duffy DM. Prostaglandin E2 acts via multiple receptors to regulate plasminogen-dependent proteolysis in the primate periovulatory follicle. Endocrinology. 2008;150:435–44.PubMedPubMedCentral

34.

Hester KE, Harper MJ, Duffy DM. Oral administration of the cyclooxygenase-2 (COX-2) inhibitor meloxicam blocks ovulation in non-human primates when administered to simulate emergency contraception. Hum Reprod. 2009;25:360–7.PubMed

35.

Duffy DM, Stouffer RL. Follicular administration of a cyclooxygenase inhibitor can prevent oocyte release without alteration of normal luteal function in rhesus monkeys. Hum Reprod. 2002;17:2825–31.PubMed

36.

Duffy DM, Stouffer RL. The ovulatory gonadotrophin surge stimulates cyclooxygenase expression and prostaglandin production by the monkey follicle. MHR Basic Sci Reprod Med. 2001;7:731–9.

37.

McCann NC, Lynch TJ, Kim SO, Duffy DM. The COX-2 inhibitor meloxicam prevents pregnancy when administered as an emergency contraceptive to nonhuman primates. Contraception. 2013;88:744–8.PubMed

38.

Yoshinaga K. Uterine receptivity for blastocyst implantation. Ann N Y Acad Sci. 1988;541:424–31.PubMed

39.

Dimitriadis E, White C, Jones R, Salamonsen L. Cytokines, chemokines and growth factors in endometrium related to implantation. Human Reprod Update. 2005;11:613–30.

40.

Brouwer J, Hazes JMW, Laven JSE, et al. Fertility in women with rheumatoid arthritis: influence of disease activity and medication. Ann Rheum Dis. 2015;74:1836–41.PubMed

41.

Akintayo RO, Aworinde OO, Ojo O, Akintayo FC, Akinlade OM, Awodun RO, et al. Is rheumatoid arthritis an innocent bystander in female reproductive problems? A comparative study of fertility in Nigerian women with and without rheumatoid arthritis. European J Rheumatol. 2018;5:179.

42.

Ince-Askan H, Dolhain RJ. Pregnancy and rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2015;29:580–96.PubMed

43.

Saketos M, Sharma N, Santoro NF. Suppression of the hypothalamic–pituitary–ovarian axis in normal women by glucocorticoids. Biol Reprod. 1993;49:1270–6.PubMed

44.

Whirledge S, Cidlowski JA. A role for glucocorticoids in stress-impaired reproduction: beyond the hypothalamus and pituitary. Endocrinology. 2013;154:4450–68.PubMedPubMedCentral

45.

Gordon D, Beastall G, Thomson J, Sturrock R. Androgenic status and sexual function in males with rheumatoid arthritis and ankylosing spondylitis. QJM Int J Med. 1986;60:671–9.

46.

O'moráin C, Smethurst P, Doré CJ, Levi A. Reversible male infertility due to sulphasalazine: studies in man and rat. Gut. 1984;25:1078–84.PubMedPubMedCentral

47.

Visser K, Katchamart W, Loza E, Martinez-Lopez J, Salliot C, Trudeau J, et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis. 2009;68:1086–93.PubMed

48.

Wallenius M, Lie E, Daltveit AK, Salvesen KÅ, Skomsvoll JF, Kalstad S, et al. Brief report: no excess risks in offspring with paternal preconception exposure to disease-modifying antirheumatic drugs. Arthritis Rheumatol. 2015;67:296–301.PubMed

49.

Weber-Schoendorfer C, Hoeltzenbein M, Wacker E, Meister R, Schaefer C. No evidence for an increased risk of adverse pregnancy outcome after paternal low-dose methotrexate: an observational cohort study. Rheumatology. 2013;53:757–63.PubMed

50.

Millsop JW, Heller MM, Eliason MJ, Murase JE. Dermatological medication effects on male fertility. Dermatol Ther. 2013;26:337–46.PubMed

51.

Puchner R, Danninger K, Puchner A, Pieringer H. Impact of TNF-blocking agents on male sperm characteristics and pregnancy outcomes in fathers exposed to TNF-blocking agents at time of conception. Clin Exp Rheumatol. 2012;30:765–7.PubMed

52.

Ramonda R, Foresta C, Ortolan A, Bertoldo A, Oliviero F, Lorenzin M, et al. Influence of tumor necrosis factor α inhibitors on testicular function and semen in spondyloarthritis patients. Fertil Steril. 2014;101:359–65.PubMed

53.

Micu MC, Micu R, Surd S, Gîrlovanu M, Bolboacă SD, Ostensen M. TNF-α inhibitors do not impair sperm quality in males with ankylosing spondylitis after short-term or long-term treatment. Rheumatology. 2014;53:1250–5.PubMed

54.

Whirledge S, Cidlowski JA. Glucocorticoids, stress, and fertility. Minerva Endocrinol. 2010;35:109.PubMedPubMedCentral

55.

Martini AC, Molina RI, Tissera AD, Ruiz RD, De Cuneo MF. Analysis of semen from patients chronically treated with low or moderate doses of aspirin-like drugs. Fertil Steril. 2003;80:221–2.PubMed

56.

Reed SD, Vollan TA, Svec MA. Pregnancy outcomes in women with rheumatoid arthritis in Washington State. Matern Child Health J. 2006;10:361–6.PubMed

57.

Wolfberg AJ, Lee-Parritz A, Peller AJ, Lieberman ES. Association of rheumatologic disease with preeclampsia. Obstet Gynecol. 2004;103:1190–3.PubMed

58.

Nørgaard M, Larsson H, Pedersen L, Granath F, Askling J, Kieler H, et al. Rheumatoid arthritis and birth outcomes: a Danish and Swedish nationwide prevalence study. J Intern Med. 2010;268:329–37.PubMed

59.

Bharti B, Lee SJ, Lindsay SP, Wingard DL, Jones KL, Lemus H, et al. Disease severity and pregnancy outcomes in women with rheumatoid arthritis: results from the organization of teratology information specialists autoimmune diseases in pregnancy project. J Rheumatol. 2015;42:1376–82.PubMed

60.

Ince-Askan H, Mandaviya PR, Felix JF, Duijts L, van Meurs JB, Hazes JM, et al. Altered DNA methylation in children born to mothers with rheumatoid arthritis during pregnancy. Ann Rheum Dis. 2019;78:1198–204.PubMed

61.

de Man YA, Hazes JM, van der Heide H, Willemsen SP, de Groot CJ, Steegers EA, et al. Association of higher rheumatoid arthritis disease activity during pregnancy with lower birth weight: results of a national prospective study. Arthritis Rheumatol. 2009;60:3196–206.

62.

Ong KK, Dunger DB. Perinatal growth failure: the road to obesity, insulin resistance and cardiovascular disease in adults. Best Pract Res Clin Endocrinol Metab. 2002;16:191–207.PubMed

63.

Leunissen RW, Kerkhof GF, Stijnen T, Hokken-Koelega A. Timing and tempo of first-year rapid growth in relation to cardiovascular and metabolic risk profile in early adulthood. JAMA. 2009;301:2234–42.PubMed

64.

Steenwinkel F, Hokken-Koelega A, Ridder MA, Hazes JM, Dolhain RJ. Rheumatoid arthritis during pregnancy and postnatal catch-up growth in the offspring. Arthritis Rheumatol. 2014;66:1705–11.PubMed

65.

de Steenwinkel FD, Hokken-koelega AC, Hazes J, Dolhain RJ. Does elevated disease activity or medication use influence the bone density of the prepubertal offspring in pregnant women with rheumatoid arthritis? Arthritis Rheum. 2013;65:S172.

66.

Ince-Askan H, Hazes JMW, Dolhain R. Breastfeeding among women with rheumatoid arthritis compared with the general population: results from a nationwide prospective cohort study. J Rheumatol. 2019;46(9):1067–74. https://doi.org/10.3899/jrheum.180805.CrossRefPubMed

67.

Murray KE, Moore L, O’Brien C, Clohessy A, Brophy C, Minnock P, et al. Updated pharmacological management of rheumatoid arthritis for women before, during, and after pregnancy, reflecting recent guidelines. Ir J Med Sci. 2019;188:169–72 (1971-).PubMed

68.

Østensen M, Andreoli L, Brucato A, Cetin I, Chambers C, Clowse ME, et al. State of the art: reproduction and pregnancy in rheumatic diseases. Autoimmun Rev. 2015;14:376–86.PubMed

69.

Østensen M, Khamashta M, Lockshin M, Parke A, Brucato A, Carp H, et al. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther. 2006;8:209.PubMedPubMedCentral

70.

Bermas BL. Non-steroidal anti inflammatory drugs, glucocorticoids and disease modifying anti-rheumatic drugs for the management of rheumatoid arthritis before and during pregnancy. Curr Opin Rheumatol. 2014;26:334–40.PubMed

71.

Skorpen CG, Hoeltzenbein M, Tincani A, Fischer-Betz R, Elefant E, Chambers C, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016;75:795–810.

72.

Weber-Schoendorfer C, Chambers C, Wacker E, Beghin D, Bernard N, NoFP C, et al. Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy: a prospective multicenter cohort study. Arthritis Rheumatol. 2014;66:1101–10.PubMed

73.

Brent RL. Utilization of animal studies to determine the effects and human risks of environmental toxicants (drugs, chemicals, and physical agents). Pediatrics. 2004;113:984–95.PubMed

74.

Cassina M, Johnson D, Robinson L, Braddock S, Xu R, Jimenez J, et al. Pregnancy outcome in women exposed to leflunomide before or during pregnancy. Arthritis Rheum. 2012;64:2085–94.PubMed

75.

Chambers CD, Johnson DL, Robinson LK, Braddock SR, Xu R, Lopez-Jimenez J, et al. Birth outcomes in women who have taken leflunomide during pregnancy. Arthritis Rheum. 2010;62:1494–503.PubMedPubMedCentral

76.

Weber-Schoendorfer C, Oppermann M, Wacker E, Bernard N, centres noFp, Beghin D, et al. Pregnancy outcome after TNF-α inhibitor therapy during the first trimester: a prospective multicentre cohort study. Br J Clin Pharmacol. 2015;80:727–39.PubMedPubMedCentral

77.

Chaudrey KH, Kane SV. Safety of immunomodulators and anti-TNF therapy in pregnancy. Curr Treat Options Gastroenterol. 2015;13:77–89.PubMed

78.

Eworuke E, Panucci G, Goulding M, Neuner R, Toh S. Use of tumor necrosis factor-alpha inhibitors during pregnancy among women who delivered live born infants. Pharmacoepidemiol Drug Saf. 2019;28:296–304.PubMed

79.

Kawai Y, Tsuchiya T, Aoki S. Pregnancy outcomes of patients exposed to adalimumab in Japan. Dig Dis. 2019;37:123–30.PubMed

80.

Malek A, Sager R, Kuhn P, Nicolaides KH, Schneider H. Evolution of maternofetal transport of immunoglobulins during human pregnancy. Am J Reprod Immunol. 1996;36:248–55.PubMed

81.

Mahadevan U, Wolf DC, Dubinsky M, Cortot A, Lee SD, Siegel CA, et al. Placental transfer of anti–tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11:286–92.PubMed

82.

Berthelsen BG, Fjeldsøe-Nielsen H, Nielsen CT, Hellmuth E. Etanercept concentrations in maternal serum, umbilical cord serum, breast milk and child serum during breastfeeding. Rheumatology. 2010;49:2225–7.PubMed

83.

Hyrich KL, Verstappen SM. Biologic therapies and pregnancy: the story so far. Rheumatology. 2013;53:1377–85.PubMed

84.

Brooks P. Use and benefits of nonsteroidal anti-inflammatory drugs. Am J Med. 1998;104:9S–13S.PubMed

85.

Wood SF. Women’s health and the FDA. N Engl J Med. 2005;353:1650–1.PubMed

86.

Østensen ME, Skomsvoll JF. Anti-inflammatory pharmacotherapy during pregnancy. Expert Opin Pharmacother. 2004;5:571–80.PubMed

87.

Østensen M. Nonsteroidal anti-inflammatory drugs during pregnancy. Scand J Rheumatol. 1998;27:128–32.

88.

Akil M, Amos R, Stewart P. Infertility may sometimes be associated with NSAID consumption. Rheumatology. 1996;35:76–8.

89.

Smith G, Roberts R, Hall C, Nuki G. Reversible ovulatory failure associated with the development of luteinized unruptured follicles in women with inflammatory arthritis taking non-steroidal anti-inflammatory drugs. Rheumatology. 1996;35:458–62.

90.

Van der Weiden R, Wouters J. Infertility may sometimes be associated with non-steroidal anti-inflammatory drug consumption. Br J Rheumatol. 1997;36:605.PubMed

91.

Nielsen GL, Sørensen HT, Larsen H, Pedersen L. Risk of adverse birth outcome and miscarriage in pregnant users of non-steroidal anti-inlammatory drugs: population based observational study and case-control study. BMJ Br Med J. 2001;322(7281):266–70.

92.

Li D-K, Liu L, Odouli R. Exposure to non-steroidal anti-inflammatory drugs during pregnancy and risk of miscarriage: population based cohort study. BMJ. 2003;327:368.PubMedPubMedCentral

93.

Nakhai-Pour HR, Broy P, Sheehy O, Bérard A. Use of nonaspirin nonsteroidal anti-inflammatory drugs during pregnancy and the risk of spontaneous abortion. CMAJ. 2011;183:1713–20.PubMedPubMedCentral

94.

Edelman AB, Jensen JT, Doom C, Hennebold JD. Impact of the prostaglandin synthase-2 inhibitor celecoxib on ovulation and luteal events in women. Contraception. 2013;87:352–7.PubMed

95.

Bata M, Al-Ramahi M, Salhab A, Gharaibeh M, Schwartz J. Delay of ovulation by meloxicam in healthy cycling volunteers: a placebo-controlled, double-blind, crossover study. J Clin Pharmacol. 2006;46:925–32.PubMed

96.

Brouwer J, Hazes J, Laven J, Dolhain R. FRI0145 High disease activity and preconceptional use of prednisone and non-steroidal anti-inflammatory drugs impair fertility in women with rheumatoid arthritis. Ann Rheum Dis. 2013;72:A419–A419419.

97.

Brubaker W, Li S, Baker L, Eisenberg M. Increased risk of autoimmune disorders in infertile men: analysis of US claims data. Andrology. 2018;6:94–8.PubMed

Titel: Fertility and infertility implications in rheumatoid arthritis; state of the art
verfasst von: Abolfazl Fattah
Amirhooman Asadi
Mohammad Reza Hooshangi Shayesteh
Forough Hatefi Hesari
Sirous Jamalzehi
Mojtaba Abbasi
Mohammad Javad Mousavi
Saeed Aslani
Publikationsdatum: 26.05.2020
Verlag: Springer International Publishing
Erschienen in: Inflammation Research / Ausgabe 8/2020
Print ISSN: 1023-3830
Elektronische ISSN: 1420-908X
DOI: https://doi.org/10.1007/s00011-020-01362-w

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Background

Purpose

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2020

The protective effects of phoenixin-14 against lipopolysaccharide-induced inflammation and inflammasome activation in astrocytes

Thick and yellowish articular effusion: a challenging diagnosis! Focus on cholesterol crystal deposition in joint

Inflammasome activation in podocytes: a new mechanism of glomerular diseases

TMEM88 modulates the secretion of inflammatory factors by regulating YAP signaling pathway in alcoholic liver disease

The unleashing of the immune system in COVID-19 and sepsis: the calm before the storm?